NCCN Guidelines® Update: Multiple Myeloma
A uniform treatment approach cannot be applied to all patients. The optimal approach to management of smoldering multiple myeloma (SMM) remains one of the most debated topics. To optimize patient outcomes, clinicians need to understand the risks and benefits of early intervention for SMM based on risk stratification and the importance of enrolling patients in clinical trials examining early intervention.
For patients with multiple myeloma (MM), the key to maximizing outcomes lies in careful choice of treatment regimens along with early recognition and management of treatment or MM-associated adverse events. Clinicians must understand the evolving therapeutic options and guidelines for administration of the available therapies in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.
The program is designed to meet the needs and improve the competence and performance of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other relevant health care professionals who manage the care of patients with cancer.
Following this program, participants should be able to:
- Select optimal therapies for patients with heavily pretreated multiple myeloma (MM) based on individual patient and disease characteristics.
- Manage toxicities of the newer agents and combination regimens in patients with MM.
- Review current management strategies of SMM and MM and effectively convey the benefits and risks of clinical trial participation to patients.
Shaji K. Kumar, MD
Mayo Clinic Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Shaji K. Kumar, MD
AbbVie, Inc.: Scientific Advisor; Grant/Research Support
Amgen Inc.: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
CARsgen Therapeutics, Ltd.: Grant/Research Support
Celgene Corporation: Scientific Advisor; Grant/Research Support
Cellectar Biosciences, Inc.: Consulting Fee
GeneCentrix, Inc.: Consulting Fee
Genentech, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor; Grant/Research Support
Kite Pharma: Grant/Research Support
MedImmune Inc.: Scientific Advisor; Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Oncopeptides: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support
sanofi-aventis U.S.: Scientific Advisor; Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor; Grant/Research Support
TeneoBio: Grant/Research Support
The faculty listed below discloses no relevant financial relationships:
Natalie K. Callander, MD
NCCN Staff Disclosures
The NCCN Leadership listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer Keller, MSS; Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.75 contact hour.
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-21-066-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing